Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

C4 Therapeutics Makes Auspicious Debut With Roche Tie-Up, $73m Series A

This article was originally published in The Pink Sheet Daily

Executive Summary

On the strength of research licensed from Dana-Farber Cancer Institute, C4 will develop targeted protein degradation therapeutics against disease-causing proteins in a range of therapeutic areas that could include cancer and the central nervous system.

You may also be interested in...



Pharmas Pursue Tech Deals To Speed Drug Development, Measure Outcomes

Deals for technology platforms allow more of a multiple-shots-on-goal approach as opposed to taking a risk with one or two candidates.

US FDA Mum On Whether Woodcock Would Stick Around Long-Term For Califf

Woodcock’s willingness to stay on at US FDA for more than a transitional period after Robert Califf’s expected confirmation as commissioner may depend on exactly the type of authority and tasks he’d be willing to delegate to her. Plus, some other agency personnel updates.

USP Nitrosamine Impurities Chapter Reflects Careful Coordination With US, EU Authorities

The USP’s general chapter on nitrosamine impurities provides guidance on assessing risks and testing levels of the carcinogens in pharmaceuticals.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS079080

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel